What is Rinri Therapeutics?
Rinri Therapeutics is a private biotechnology firm established in late 2018 and headquartered in Sheffield, UK. The company is dedicated to pioneering stem cell-based therapies aimed at restoring hearing. Its focus on regenerative medicine positions it within a rapidly evolving sector of the healthcare industry, addressing a critical unmet medical need.
How much funding has Rinri Therapeutics raised?
Rinri Therapeutics has raised a total of $19.4M across 3 funding rounds:
Angel/Seed
$985K
Unspecified
$13.9M
Grant
$4.5M
Angel/Seed (2019): $985K, investors not publicly disclosed
Unspecified (2021): $13.9M led by Boehringer Ingelheim Venture Fund
Grant (2021): $4.5M supported by Innovate UK
Key Investors in Rinri Therapeutics
Innovate UK
Innovate UK, an innovation agency, has provided grant funding, reflecting governmental support for pioneering scientific advancements in the UK. Its historical role as the Technology Strategy Board highlights a commitment to fostering technological development.
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund is an active investor focused on first-in-class, disease-modifying therapeutics. Their investment in Rinri Therapeutics signals a strategic interest in novel approaches to healthcare and a belief in the company's potential to redefine care standards.
What's next for Rinri Therapeutics?
With the recent infusion of capital, Rinri Therapeutics is poised for significant advancement in its research and development pipeline. The company's strategic investment suggests a focus on scaling operations, potentially moving towards clinical trials and further validating its innovative stem cell technology for hearing restoration. This enterprise-level funding indicates strong confidence from investors in the company's long-term vision and therapeutic potential.
See full Rinri Therapeutics company page
